Biotechs sell hemophilia B vaccine
Ipsen and Inspiration agreed jointly to sell their respective commercialization rights for the vaccine, called IB1001, as part of the deal. Cangene now has worldwide rights to IB1001, a recombinant factor IX vaccine that is currently undergoing regulatory review in Europe and the United States.
Cangene has also acquired Inspiration's rights to two product candidates that are currently in clinical development, IB1007 (recombinant FVIIa) and IB1008 (recombinant FVIII). Cangene agreed to pay up to $50 million in potential additional commercial milestones and $5.9 million up front.
The U.S. Food and Drug Administration has placed IB1001 on clinical hold as part of the review process. The agency is concerned about the presence of host cell proteins in the vaccine. Inspiration said it believes it has been successful at eliminating the problem using both original and modified manufacturing processes.
Ipsen and Inspiration agreed last month to sell a recombinant porcine FVIII, known as OBI-1, to Baxter International. The U.S. Bankruptcy Court in Boston approved the sale in January and the U.S. Federal Trade Commission is reviewing the trade under the Hart-Scott-Rodino Act.